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Introduction
Osteosarcomas (OSs) and the Ewing sarcoma family of tumors
(ESFT) are the most common malignant bone tumors among children
and adolescents [1]. With a multidisciplinary treatment approach, the
survival of patients with localized OSs and the ESFT has improved [2].
Usually, the treatment scheme for patients with OSs or the ESFT is
comprised of pre-operative chemotherapy, local treatment, and post-
operative chemotherapy. Originally, pre-operative chemotherapy was
introduced to compensate for the time needed for custom-made
prostheses and increase the feasibility of limb salvage surgery [3]. 
The response to pre-operative chemotherapy is closely related to
thelong-term survival of patients with bone tumors and can be esti-
mated in variety of ways. Clinically, patients with responding tumors
might show a decrease in pain or swelling of the affected limb. A
decrease in tumor vascularity and edema on computed tomography
(CT) or magnetic resonance imaging (MRI) is considered to be a sign
Purpose
Response to neo-adjuvant chemotherapy is an important prognostic factor for osteosarcoma
(OS) and the Ewing sarcoma family of tumors (ESFT). [F-18]-fluorodeoxy-D-glucose (FDG)-
positron emission tomography (PET) is a non-invasive imaging modality that predicts his-
tologic response to chemotherapy of various malignancies; however, limited data exist about
the usefulness of FDG-PET in predicting the histologic response of pediatric bone tumors to
chemotherapy. We analyzed the FDG-PET imaging characteristics of pediatric bone tumors
and determined the association with response to chemotherapy. 
Materials and Methods
Pediatric patients with OS (n=19) or ESFT (n=17) were evaluated for FDG-PET standard
uptake values before (SUV1) and after (SUV2) chemotherapy. The relationship to the che-
motherapy response was assessed by histopathology in surgically-excised tumors. A com-
plete data set (SUV1, SUV2, and histologic response) was available in 23 patients.
Results
While the mean SUV1s were not different between patients with OSs and ESFTs (9.44 vs.
6.07, p=0.24), the SUV2s were greater in the patients with OSs than ESFTs (4.55 vs. 1.66,
p=0.01). The ratios of SUV2-to-SUV1 (SUV2 : SUV1) were 0.65 and 0.35 for OS and ESFT, re-
spectively (p=0.08). All of the patients with ESFTs and 47% of the patients with OS had a fa-
vorable histologic response to chemotherapy. The SUV2 : 1 [(SUV1-SUV2)/SUV1]0.5 and
SUV22.5 were related to favorable histologic responses to chemotherapy; the sensitivity
and specificity of SUV2 : 1 at 0.5 and SUV2 at 2.5 were 93% and 88%, and 88% and 78%,
respectively. 
Conclusion
FDG-PET can be used as a non-invasive surrogate to predict response to chemotherapy in
children with bone tumors.
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suggesting a favorable response to chemotherapy. However, radiologic
imaging has some limitations. The actual size of OSs does not change
after chemotherapy and it is difficult to evaluate osseous reactions
objectively [1,4]. Therefore, it is difficult to distinguish responding
tumors from non-responding tumors by CT or MRI [4,5]. Histologic
responses are determined on surgically-resected tumor specimens and
usually graded according to the portion of viable tumor cells. The histo-
logic response is considered to be the most reliable prognostic indicator
for survival of patients with OSs and the ESFT [1,5]. However, the
histologic response can only be obtained after surgery, and might not
always be available due to inoperable tumors. Thus, a surrogate is
needed that can evaluate the response to chemotherapy. 
[F-18]-fluorodeoxy-D-glucose (FDG)-positron emission tomo-
graphy (PET) is a new imaging tool in the field of oncology. FDG is an
analogue of glucose; FDG is taken up by cells to the same extent as
glucose, but FDG is not metabolized [6]. FDG-PET represents glucose
metabolism of the tissue. Some organs, such as the brain, myocardium,
and kidneys show a high physiologic accumulation in the normal state.
FDG uptake can be enhanced by inflammation or cancer. FDG is
trapped into the cancer cells due to the high glycolytic activity, and
malignant tumors, especially in active state, often show increased
glycolytic activity [7]. Therefore, FDG-PET is regarded as an effective
modality for evaluating the response to chemotherapy. It has been
reported that changes in FDG-PET imaging following neo-adjuvant
chemotherapy are predictive of the histologic response in patients with
breast cancers [8,9], head and neck cancers [10], lymphomas [11,12],
and gastrointestinal stromal tumors [13] of adults. Recent studies have
shown that integrated PET-CT is more accurate for lesion localization
and characterization than PET and CT alone or the results obtained
from PET and CT separately [14]. In contrast to adult cancers, few stu-
dies have been performed in children with cancer regarding the FDG-
PET image characteristics and the association with the response to che-
motherapy. Moreover, controversy exists about the appropriate use of
FDG-PET in children due to the concern of excessive radiation ex-
posure. 
In this retrospective study we evaluated the FDG-PET image
findings in children with OSs and the ESFT. We focused on the FDG-
PET image changes after chemotherapy and the relationship to the
histologic response.
Materials and Methods
1 Patients and treatments
Thirty-six pediatric patients were enrolled in this retrospective study;
the clinical characteristics of the patients are summarized in Table 1.
One patient was excluded because of age (ĥ18 years). Due to inope-
rable tumors or loss of records, data regarding histologic responses
were not available in 8 patients. Standardized uptake value before
chemotherapy (SUV1) were not available for four patients who were
referred to our institution. Twenty-three patients (13 with OSs and 10
with the ESFT) had complete data sets (SUV1, standardized uptake
value after chemotherapy [SUV2], and histologic responses), therefore
they comprised the final study population. 
OSs or the ESFT were diagnosed based on histologic examination
of representative specimens obtained by open or needle biopsy and by
resection. The extent of the tumors was evaluated by plain radiography
and MRI. To determine the presence of metastases, 99mTc-methylene
diphosphonate whole-body bone scintigraphy and CT of the chest
were performed. Generally, patients were treated with pre-operative
chemotherapy, surgery, and post-operative chemotherapy. Histologic
response to pre-operative chemotherapy was evaluated using a resected
tumor specimen, and were classified as follows:ģ10% viable tumor
cells indicated a good response; and10% residual viable tumor
indicated a poor response. Informed consent was required from all
patients and/or their legal guardians.
2 PET imaging 
FDG-PET imaging was performed twice in every patient (at the
time of diagnosis and before surgery). After fasting for at least 4-6
hours, patients received FDG intravenously; the dose of FDG was
Table 1. Clinicopathologic characteristics of patients
Characteristics No. of patients (%)
Age (range, yr) 9.5 (3-19)
Gender Male 25 (69)
Female 11 (31) 
Diagnosis OS 19 (53)
ESFT 17 (47) 
Location Extremity 30 (83)
Axial 6 (17)
Primary site Distal femur 8 (22)
Proximal femur 4 (11)
Proximal tibia 7 (19)
Pelvis 5 (14)
Humerus 1 (3)
Others 11 (31)
Pre-operative MMCA 18  (50)
chemotherapy VIDE 12 (33)
Others 6 (17)
Metastasis at  Present
a) 6 (17)
diagnosis Absent 30 (83)
Surgery Yes 28 (78)
No 8 (22)
Histologic response Good 19 (68)
Poor 9 (32)
OS, osteosarcoma; ESFT, Ewing sarcoma family of tumors; M, high-dose
methotrexate; C, cisplatin; A, doxorubicin; V, vincristine; I, ifosfamide; D,
doxorubicin; E, etoposide. 
a)The sites of metastasis were the lung in 4 cases and
bone in 2 cases.Cancer Res Treat. 2011;43(3):170-175
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Histologic FDG-PET  findings
response SUV1 p-value SUV2 p-value SUV2 : 1 p-value
Overall Good 7.91±6.41 (n=15) 0.95 2.04±1.01 (n=18) 0.04 0.69±0.20 (n=15) ģ0.01
Poor 8.10±7.50 (n=8) 6.36±5.13 (n=9) 0.13±0.48 (n=8)
OS Good 11.58±9.72 (n=5) 0.48 2.53±1.06 (n=8) 0.06 0.69±0.14 (n=5) 0.03
Poor 8.10±7.50 (n=8) 6.36±5.13 (n=9) 0.13±0.48 (n=8)
ESFT Good 6.07±3.28 (n=10)  1.66±0.82 (n=10)  0.69±0.23 (n=10)  
Poor   
Table 2. FDG-PET findings and histologic response 
Values are presented as the mean±standard deviation. FDG-PET, [F-18]-fluorodeoxy-D-glucose-positron emission tomography; SUV, standard uptake value; SUV2:1, decreased
SUV ratio, i.e., (SUV1-SUV2)/SUV1; OS, osteosarcoma; ESFT, Ewing sarcoma family of tumors.
MRI
PET-CT
Before chemotherapy After chemotherapy
Max SUV=27.4 Max SUV=1.9
A
MRI
PET-CT
Before chemotherapy After chemotherapy
Max SUV=5.9 Max SUV=1.6
B
Osteosarcoma ESFT
Fig. 1. Magnetic resonance imaging (MRI) and [F-18]-fluorodeoxy-D-glucose-positron emission tomography (FDG-PET) findings before and
after chemotherapy in children with bone tumors. (A) A 10-year-old boy with an osteosarcoma of the right proximal tibia. Standard uptake value
(SUV) markedly decreased after chemotherapy (27.4 to 1.9) and the tumor showed a favorable histologic response (95% necrosis). (B) A 10-
year-old girl with Ewing sarcoma family of tumors (ESFT) of the left proximal femur showed a complete histologic response (100% necrosis) to
chemotherapy. SUV1 and SUV2 values were 5.9 and 1.6, respectively. CT, computed tomography.Dong Hwan Kim, et al_FDG-PET and Chemotherapy Response in Pediatric Bone Tumors
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based on body weight (5 mCi for children weighingģ30 kg, and 10
mCi for children weighing  30 kg). Whole body scans were obtained
after 45-60 minutes of equilibration time. SUVs were calculated
throughout the tumor. We chose the maximum SUV for our study
rather than the average SUV. SUV1 and SUV2 represented the
maximum tumor SUVs at the time of diagnosis and before surgery,
respectively. SUV2 : 1 represented the decreased SUV ratio, i.e., (SUV1-
SUV2)/SUV1. 
3 Statistical analysis
A two sample t-test was used to compare the mean values of SUV1,
SUV2, and SUV2 : 1 between the two groups (OS vs. ESFT and good
responder vs. poor responder). Fisher’s exact test was used to compare
categorized variables (according to SUV values) in the good and poor
responder groups. All calculations were performed using SPSS ver.
17.0 (SPSS Inc., Chicago, IL), and p-valueģ0.05 were considered
significant. 
Results
1 FDG-PET findings before and after chemotherapy
Data regarding SUV1 from four patients were not available because
the patients were transferred from other hospitals. Therefore, a
complete data set (SUV1, SUV2, and histologic response) were
available in 23 patients. The FDG-PET imaging and histologic
response data for OS and ESFT patients are presented in Table 2. The
mean SUV1 from patients with OSs and the ESFT did not have a
meaningful difference (9.44 vs. 6.07, respectively, p=0.24). However,
the mean SUV2 of OSs was significantly higher than the ESFT (4.55
vs. 1.66, respectively, p=0.01). The mean SUV2 : 1 of the ESFT was
significantly higher than the OSs (0.69 vs. 0.35, respectively, p=0.05).
Fig. 1 shows the representative FDG-PET and MRI prior to and after
neo-adjuvant chemotherapy for two patients. A 10-year-old boy with
an OS of the right proximal tibia showed markedly decreased SUV2
after chemotherapy (SUV1, 27.4; SUV2, 1.9) and the tumor showed a
favorable histologic response (95% necrosis). The SUV1 and SUV2
values of a 10-year-old girl with the ESFT of the left proximal femur
were 5.9 and 1.6, respectively.
2 FDG-PET findings and histologic response to
chemotherapy
SUV2 and SUV2 : 1 was closely related to the histologic response.
The mean SUV2 of poor responders was significantly higher than
good responders (2.04 vs. 6.36, respectively, p=0.04). The mean SUV2 : 1
of good responders was significantly higher than the mean SUV2 : 1 of
poor responders (0.69 vs. 0.13, respectively, pģ0.01). There were
more good responders in patients with a SUV22.5 (pģ0.01) (Fig.
2). The sensitivity and specificity at SUV22.5 were 88% and 78%,
respectively. The positive and negative predictive values to be good
responders at SUV22.5 were 88% and 70%, respectively. The SUV2 : 1
0.5 appeared to be related to a favorable histologic response (p
ģ0.01) (Fig. 2). The sensitivity and specificity at a SUV2 : 10.5 were
93% and 88%, respectively. The positive and negative predictive
values to be good responders at SUV2 : 10.5 were 93% and 78%,
respectively. 
While 47% of the patients with OSs were good responders, all of the
patients with the ESFT were good responders (pģ0.01), therefore
further statistical analysis was not performed for the patients with the
ESFT.
For patients with OSs, the mean SUV2 of good responders tended to
be lower than poor responders (2.53 vs. 6.36, respectively, p=0.06).
The mean SUV2 : 1 of good responders was significantly higher than
poor responders (0.69 vs. 0.13, respectively, p=0.03). There were more
good responders in patients with a SUV22.5 (p=0.04). The sen-
sitivity and specificity at SUV22.5 were 75% and 78%, respectively.
The positive and negative predictive values for good responders at
SUV22.5 were 75% and 78%, respectively. The SUV2 : 10.5 ap-
peared to be related to a favorable histologic response (pģ0.01). The
sensitivity and specificity at SUV2 : 10.5 were 83% and 88%, re-
spectively. The positive and negative predictive values to be good re-
sponders at SUV2 : 10.5 were 83% and 100%, respectively. The cor-
relation between the SUV cut-off value and response to neo-adjuvant
chemotherapy is summarized in Fig. 2, and shows the correlation
between SUV2, SUV2 : 1, and histologic responses. 
Good
Poor
SUV2 SUV2:1
2
(22.2%)
13
(92.9%)
15
(88.9%)
2
7 7
1
<2.5 >2.5 <0.5 >0.5
p<0.01 p<0.01
3
(30.0%)
Fig. 2. Histologic response and SUV2, SUV2 : 1, SUV22.5, and
SUV2:10.5 were related to a favorable histologic response to
chemotherapy. SUV, standard uptake value; SUV2 : 1, decreased SUV
ratio, i.e., (SUV1-SUV2)/SUV1.Cancer Res Treat. 2011;43(3):170-175
174 CANCER  RESEARCH AND  TREATMENT
Discussion
In this study, we have shown that imaging characteristics obtained
by FDG-PET are correlated with tumor activity. SUV2 and SUV2 : 1
have a significant correlation with histologic responses to neo-adjuvant
chemotherapy and are a powerful candidate that can predict the re-
sponse to neo-adjuvant chemotherapy before surgery in a non-invasive
manner. 
FDG-PET findings, especially the maximum SUVs, are the most
reliable units by which to evaluate tumor activity. It has been reported
that an initial high FDG uptake is predictive of poor overall and event-
free survival of patients with OSs [15]. We did not find any differences
in the SUV1, i.e., the initial FDG uptake values between good and poor
responders; however, there were changes in the FDG-PET charac-
teristics, i.e., SUV2 was related to the response to chemotherapy. After
administration of chemotherapy, changes in FDG metabolism can
occur as rapidly as 8 hours [16]. We showed that low SUV2 values
were related to favorable responses and a SUV2ģ2.5 was suggested
to be a meaningful cut-off value [1,4,17]. A SUV2 : 1 of 0.5 was shown
to have statistical significance, which is in agreement with other studies
[1,4,17]. 
Differences exist between OSs and the ESFT in the response to
chemotherapy and the corresponding FDG-PET changes. In patients
with OSs, a SUV2 of 2.5 and a SUV2 : 1 of 0.5 had the most reliable
statistical significance, as in other studies [1,4,17]. SUV2 : 1 had a more
evident correlation with the histologic response than SUV2. SUV2
may remain elevated because of inflammation or reactive changes
without viable residual tumor [18]. Moreover, tumors with an initial
high SUV1 might still have a high SUV2, despite a significant de-
crease in the SUV value. Therefore, the SUV2 : 1, which reflects a de-
creased ratio of the SUV value, might be a more reliable indicator for
evaluating the response to chemotherapy than SUV2. An alternative
possibility is that the evaluation of tumor response averages the
percentage of tumor necrosis across the entire resected tumor speci-
men, whereas we reported the maximal SUV within the tumor as the
SUV2 [1]. For patients with the ESFT, the mean SUV2 and SUV2 : 1
was 1.66 and 0.69, respectively. Because all of the patients had a fa-
vorable response to chemotherapy, we could not analyze the asso-
ciation between SUV changes and histologic response of the ESFT.
For patients with the ESFT, we presume that role of FDG-PET in pre-
dicting chemotherapy response might be more prominent in refractory
or relapsed cases.  
Our study had several limitations. First, selection bias might have
existed in our study because we excluded 8 cases that were initially
enrolled. Second, a small sample size limited the statistical confidence
for positive and negative predictive values. We found that FDG-PET
findings were related to the histologic response to chemotherapy,
which is considered to be the most important prognostic factor.
However, the impact on survival is still elusive. The histologic
response might not represent the response of the entire tumor, rather a
representative section. Lewis et al. [19] has demonstrated that a good
histologic response to pre-operative chemotherapy did not translate into
a demonstrable patient benefit in overall or progression-free survival.
Further investigation with a larger sample size and longer follow-up
duration is necessary. 
Conclusion
FDG-PET findings (SUV2 and SUV2 : 1) were shown to be related to
the histologic responses to chemotherapy of pediatric patients with
bone tumors. We believe that FDG-PET is a powerful tool that can
predict the response to chemotherapy before surgery. Because our
findings are retrospective in nature and based on data from a small
sample, further studies are necessary to elucidate the relationship
between FDG-PET findings and treatment outcomes of children with
malignant bone tumors.
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